Salmeterol/fluticasone combination lowers asthma exacerbations

Teplizumab is being evaluated to delay type 1 diabetes. The PDUFA date is August 17, 2022.

Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.

Data is being presented at the 10th Annual IDWeek Virtual Conference, September 29 to October 3.

The flu program is the first in programs leveraging BioNTech’s mRNA technology for vaccines for other respiratory viruses, oncology, and genetic diseases.

Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.

Point32Health is the name of the not-for-profit health care organization formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan.